
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
Roquette has completed its previously announced acquisition of Itacel, an excipient division of Blanver.
On Sept. 1, 2017, Roquette, a French biopharmaceutical company specializing in plant-based excipients, completed the
The acquisition is part of a
Source:






